The ever-expanding scope of modern anti-cancer therapy to include radiotherapy, targeted therapies, and immunotherapy have revolutionized cancer treatment opportunities to increase the number of survivors but has also resulted in significant cancer treatment-related cardiovascular disease (CTRCD). The emerging crux of cardio-oncology is to prevent and treat these cardiovascular (CV) toxicities, during or after anti-cancer therapy, in order to empower oncologists to continue life-saving or life-prolonging treatment, regardless of the potential cardiac-toxicities to achieve better overall outcomes for cancer patients.
We need new as well as long-term cardiovascular toxicities and outcomes of cancer treatments to be reported. This can take the form of real-world, collaborative and prospective data on incidence, diagnosis, affected demographics, clinico-radiological & laboratory characteristics, treatment and outcomes of CTRCD. This data can then be subsequently utilized for prognostication and formulation of guidelines beyond expert opinion and surveys. New, emerging, and rare cardiovascular toxicities and their management as seen with newer anti-cancer treatment modalities in post-marketing surveillance needs to be published urgently.
This Research Topic serves to collect real-world as well as validated prospective data on CTRCD. This includes the entire spectrum of cancer treatment-related cardiovascular diseases including systemic and pulmonary hypertension, arrhythmias, thromboembolism, coronary heart disease, valvular dysfunction, autonomic dysfunction and pericardial disease. Other themes like cardioprotective strategies during cancer treatment, clinical use of cardiac biomarkers, optimization of nutritional care and exercise, and also cost-effectiveness, disparity in care, policy-making, global or community efforts in cardio-oncology, anti-cancer drug review and reporting of CV outcomes and toxicities in new anti-cancer drug trials, CV comorbidity management and risk stratification in cancer, and cancer survivorship will also be covered in the scope of the collection.
The different types of manuscript invited include original research articles, case reports or case series, review articles, letters to the editors or short communications, perspectives and clinical trial reports.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
The ever-expanding scope of modern anti-cancer therapy to include radiotherapy, targeted therapies, and immunotherapy have revolutionized cancer treatment opportunities to increase the number of survivors but has also resulted in significant cancer treatment-related cardiovascular disease (CTRCD). The emerging crux of cardio-oncology is to prevent and treat these cardiovascular (CV) toxicities, during or after anti-cancer therapy, in order to empower oncologists to continue life-saving or life-prolonging treatment, regardless of the potential cardiac-toxicities to achieve better overall outcomes for cancer patients.
We need new as well as long-term cardiovascular toxicities and outcomes of cancer treatments to be reported. This can take the form of real-world, collaborative and prospective data on incidence, diagnosis, affected demographics, clinico-radiological & laboratory characteristics, treatment and outcomes of CTRCD. This data can then be subsequently utilized for prognostication and formulation of guidelines beyond expert opinion and surveys. New, emerging, and rare cardiovascular toxicities and their management as seen with newer anti-cancer treatment modalities in post-marketing surveillance needs to be published urgently.
This Research Topic serves to collect real-world as well as validated prospective data on CTRCD. This includes the entire spectrum of cancer treatment-related cardiovascular diseases including systemic and pulmonary hypertension, arrhythmias, thromboembolism, coronary heart disease, valvular dysfunction, autonomic dysfunction and pericardial disease. Other themes like cardioprotective strategies during cancer treatment, clinical use of cardiac biomarkers, optimization of nutritional care and exercise, and also cost-effectiveness, disparity in care, policy-making, global or community efforts in cardio-oncology, anti-cancer drug review and reporting of CV outcomes and toxicities in new anti-cancer drug trials, CV comorbidity management and risk stratification in cancer, and cancer survivorship will also be covered in the scope of the collection.
The different types of manuscript invited include original research articles, case reports or case series, review articles, letters to the editors or short communications, perspectives and clinical trial reports.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
